4 news items
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
SLGL
28 May 24
to prevent the new basal cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
SLGL
20 May 24
) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Sol-Gel is conducting
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
SLGL
16 May 24
carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
SLGL
13 Mar 24
(BCC) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Sol-Gel
- Prev
- 1
- Next